New Approaches in MASLD Management Highlight Early Intervention
The management of Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is undergoing significant changes. Traditionally managed with lifestyle advice and routine monitoring, MASLD is now recognized as a systemic metabolic condition requiring early and comprehensive intervention. This shift is driven by new evidence suggesting that early detection and management of metabolic risks can lead to better outcomes. The disease, affecting an estimated 30% of the global adult population, is linked to conditions like diabetes and obesity and can progress to severe liver damage if untreated. The new approach emphasizes coordinated care, emerging treatments, and advanced monitoring tools to address the broader factors driving liver damage.